EarliPoint Health receives expanded FDA clearance for autism assessment in children up to age 8.

Read Release →

News & Media

News and announcements highlighting our ongoing work in early developmental science and clinical innovation.

Featured news

CNN

Eye-tracking tool may help diagnose autism more quickly and accurately, new studies suggest

NBC News

Autism may be identified early with eye-tracking device, studies show

TechCrunch

Deal Dive: EarliTec Diagnostics raises $21.5M to help diagnose autism earlier

Fierce Biotech

FDA clears digital tool to help diagnose autism in children as young as 16 months

JAMA / BusinessWire

JAMA publishes two large studies demonstrating diagnostic accuracy of EarliPoint Evaluation

LinkedIn

When a Year Is Too Long: NJ Nonprofit Dramatically Reduces Wait Times for Autism Evaluation

More coverage

Mission Viewpoint

Operator Spotlight: Lighthouse Autism Center scales diagnostics with rigor

SEMO

Southeast Missouri State University Expands Autism Testing for Children Up to Age 8

The Den

New program expands early autism diagnosis for children in rural Georgia

Contemporary Pediatrics

FDA-cleared tool could assist in diagnosing autism

BehaviorLive

Real-World Perspectives: Integrating EarliPoint Into Clinical Autism Assessment

HCPLive

Eye-Tracking Device Predicts Expert Autism Diagnoses

Deseret News

Is eye-tracking device a simpler way to detect autism?

MD+DI

A Better AI Tool for Diagnosing & Assessing Autism

The Transmitter

New tablet-based tools to spot autism draw excitement — and questions

Behavioral Health Business

Autism Device Company EarliTec Raises $21.5M 

Medical Design & Outsourcing

Explainable AI lessons from the developers of the EarliPoint Evaluation for autism

Disability Scoop

FDA Approved Eye-Tracking Device May Speed Autism Diagnosis, Studies Suggest

Latest News

From Social Attention to Generative Language: Rethinking Early Autism Intervention

April 6, 2026

Science, Advocacy, and Early Detection: Fixing the Autism Bottleneck

February 27, 2026

Real-World Perspectives: Integrating EarliPoint Into Clinical Autism Assessment

February 24, 2026

What Families Actually Need: Rethinking Autism Care Tools

February 24, 2026

Building Independence Through the Self & Match System

November 12, 2025

From Data to Documentary: Inspiring Understanding and Change Through the Art and Science of Storytelling

November 10, 2025

Get in Touch

For press inquiries, interview requests, or media resources.
Contact Press Team
Request A Demo

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder